Recent survey by AIM Group International, published in M&C Asia, June 18, 2021, revealed a strong desire to return to in-person meetings.
The global meeting and event management organiser surveyed 200 representatives of pharmaceutical and biopharma companies from across all therapeutic areas.
Of these, half are ready to sponsor in-person events in Q3 2022. Just 16% exclude it as an option, while the remaining 37% opted to decide later.
For 2021, event budgets are mostly allocated to in-person or hybrid events (43%), while digital-only events are preferred by one in three companies (35%).
In that 43% mix — majority of votes still went to in-person participation (52%), or both in person and online (31%).